Company Market News
|
Takeda Pharmaceutical Co. Ltd.
(NYSE: TAK)
|
9:00 PM UTC, 12/12/25 | |||
|---|---|---|---|---|
| Last: $14.33 | Change: -0.06 | %Change: -0.42% | Volume: 2,123,444 | |
Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal
Back
Last updated: 01/21/2025 9:15:52 AM
Back
Last updated: 01/21/2025 9:15:52 AM
09:15 AM EST, 01/21/2025 (MT Newswires) -- Keros Therapeutics (KROS) said Tuesday that it will receive a $200 million upfront payment from Takeda Pharmaceutical (TAK) in connection to a global development and commercialization license deal to advance elritercept.
The license agreement with Takeda took effect on Jan. 16, the biopharmaceutical company said.
Keros shares were up 5% and Takeda shares were edging 0.3% higher in recent premarket activity.
http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
